Literature DB >> 25504355

Ethical perspectives on translational pharmacogenetic research involving children.

Parvaz Madadi1.   

Abstract

Children represent a special population characterized by dynamic changes which may affect drug safety and efficacy. The interplay of pharmacogenetics with physiological alterations that occur throughout development is an area of increasing research focus. Given the translational nature of pharmacogenetic research, it is possible that pharmacogenetic research results may possess clinically actionable information. The potential long-term implications of pharmacogenetic test results throughout the lifespan of the child, and the potential impact of the results for other members of the family need to be considered. Comprehensive counselling and communication strategies may need to be integrated as part of pharmacogenetic research studies in children.

Entities:  

Mesh:

Year:  2015        PMID: 25504355     DOI: 10.1007/s40272-014-0111-3

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  31 in total

1.  Codeine, ultrarapid-metabolism genotype, and postoperative death.

Authors:  Catherine Ciszkowski; Parvaz Madadi; Michael S Phillips; Albert E Lauwers; Gideon Koren
Journal:  N Engl J Med       Date:  2009-08-20       Impact factor: 91.245

Review 2.  Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine.

Authors:  Felix W Frueh
Journal:  Pharmacogenomics       Date:  2009-07       Impact factor: 2.533

Review 3.  Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.

Authors:  Susanne B Haga; Rachel Mills; Hayden Bosworth
Journal:  Patient Educ Couns       Date:  2014-06-21

4.  Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.

Authors:  S B Haga; W Burke
Journal:  Clin Pharmacol Ther       Date:  2011-07       Impact factor: 6.875

5.  The emergence of an ethical duty to disclose genetic research results: international perspectives.

Authors:  Bartha Maria Knoppers; Yann Joly; Jacques Simard; Francine Durocher
Journal:  Eur J Hum Genet       Date:  2006-07-26       Impact factor: 4.246

6.  Primary care physicians' knowledge of and experience with pharmacogenetic testing.

Authors:  S B Haga; W Burke; G S Ginsburg; R Mills; R Agans
Journal:  Clin Genet       Date:  2012-07-03       Impact factor: 4.438

7.  Attitudes of 47 mothers of pediatric oncology patients toward genetic testing for cancer predisposition.

Authors:  A F Patenaude; L Basili; D L Fairclough; F P Li
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

8.  Incidental findings in clinical genomics: a clarification.

Authors: 
Journal:  Genet Med       Date:  2013-07-04       Impact factor: 8.822

9.  Survey of US public attitudes toward pharmacogenetic testing.

Authors:  S B Haga; J M O'Daniel; G M Tindall; I R Lipkus; R Agans
Journal:  Pharmacogenomics J       Date:  2011-02-15       Impact factor: 3.550

10.  Delivering pharmacogenetic testing in a primary care setting.

Authors:  Rachel Mills; Deepak Voora; Bruce Peyser; Susanne B Haga
Journal:  Pharmgenomics Pers Med       Date:  2013-09-18
View more
  2 in total

1.  Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations.

Authors:  Susan M Wolf; Rebecca Branum; Barbara A Koenig; Gloria M Petersen; Susan A Berry; Laura M Beskow; Mary B Daly; Conrad V Fernandez; Robert C Green; Bonnie S LeRoy; Noralane M Lindor; P Pearl O'Rourke; Carmen Radecki Breitkopf; Mark A Rothstein; Brian Van Ness; Benjamin S Wilfond
Journal:  J Law Med Ethics       Date:  2015       Impact factor: 1.718

2.  Creating a new ethical climate for drug research in children and pregnant women.

Authors:  Doreen Matsui; Gideon Koren
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.